Archive

October 2026 · Risk score 7/10

The September 28 US-China '30-for-30' tariff deal reduces near-term trade-war intensity, but elevated input-cost inflation (ISM Prices Paid at 71.1 in August, forecast higher in September), a Fed funds rate now at 3.75-4.00%, and a January 10 trade-truce expiry keep structural cost and policy risk firmly elevated for manufacturers entering Q4 2026.

September 2026 · Risk score 7/10

Three converging pressures, a hawkish Fed pivot risk on September 16, the September 29 activation of Section 232 pharmaceutical tariffs for smaller manufacturers, and a third consecutive month of decelerating US manufacturing PMI, compress margins and capital planning horizons across the sector simultaneously.

August 2026 · Risk score 8/10

A simultaneous tariff escalation on Canada, a multi-front Section 301 action against 16 manufacturing economies, and a five-month Hormuz supply disruption are compressing manufacturer margins from three directions at once, with a divided Fed unable to cut rates into the inflationary pressure.

July 2026 · Risk score 8/10

Four unrelated trade instruments land inside one July window: the United States declines to renew USMCA on the 1st, a Commerce Section 232 semiconductor review reports out the same day, a 100 percent duty on patented pharmaceuticals takes effect on the 31st, and the Section 122 surcharge expires on the 24th. China's heavy rare-earth and magnet licensing stays fully in force while its gallium and germanium suspensions count down to a November cliff, keeping input risk elevated across every manufacturing subsector.